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Introduction
============

Tonsillectomy with or without adenoidectomy is one of the most commonly performed ear, nose, and throat surgeries worldwide.[@ref1] [@ref2] After this intervention, many patients have nausea, vomiting, and pain.[@ref3] [@ref4] Without prophylaxis, the reported incidence of postoperative vomiting in children undergoing tonsillectomy ranges from 40% to 73%.[@ref5] [@ref6] [@ref7] [@ref8] Systemic steroids have been shown to be as efficient as 5-HT~3~ antagonists and droperidol in reducing postoperative nausea and vomiting.[@ref8] Their use is increasing and currently recommended in recent guidelines of the American Academy of Otolaryngology-Head and Neck Surgery Foundation for tonsillectomy in children.[@ref9] [@ref10] Furthermore, some studies suggest that steroids could be associated with an earlier return to a regular diet after tonsillectomy.[@ref2] [@ref11]

A recent randomised controlled trial comparing different doses of dexamethasone for preventing postoperative nausea and vomiting after tonsillectomy showed an increased incidence of postoperative bleeding and reoperation due to bleeding in the steroid group.[@ref12] Previous observational studies have also reported this association.[@ref13] [@ref14] A recent meta-analysis on dexamethasone and tonsillectomy bleeding found no increased risk of postoperative bleeding with the use of steroids.[@ref15] However, this review was not exhaustive and did not evaluate clinically significant outcomes such as operative reinterventions.

Considering the frequent use and potential harm of systemic steroids to prevent postoperative nausea and vomiting after tonsillectomy, and the existence of effective alternatives such as 5-HT~3~ antagonists,[@ref10] we conducted a systematic review of randomised controlled trials to evaluate the risk of postoperative bleeding and of operative reinterventions after systemic steroids use in patients undergoing tonsillectomy.

Methods
=======

Design and search strategy
--------------------------

We conducted a systematic review and meta-analysis of randomised controlled trials. A search strategy was developed for Medline (OVID, 1950-March 2011), Embase (OVID, 1947-March 2011), and the Cochrane Central Register of Controlled Trials (up to March 2011) (web appendix). We identified randomised controlled trials by incorporating validated filters for Medline[@ref16] and Embase.[@ref17] We also did a similar search of Scopus, the Web of Science, and Intute databases, as well as OpenSIGLE, Google Scholar, and the National Technical Information Service databases for the grey literature. Relevant abstracts and conference proceedings were identified using the Biosis database. References of pertinent reviews identified in the search were scanned to identify potentially relevant trials. Two reviewers (JP, LV) independently screened all studies for eligibility by titles and abstracts, and by full text publications if needed. A third reviewer (AFT) was consulted in instances when consensus could not be reached between the two reviewers. At the end of this selection process, Google Scholar was used to identify authors that cited any of the included studies. Additional studies identified by this method were then considered for eligibility.

Study eligibility
-----------------

All randomised controlled trials of tonsillectomy (any indications) that compared the administration of any systemic steroids to any comparator (other intervention, placebo, or no intervention) were included, provided that bleeding or the absence of bleeding episodes (of any severity) were also reported or could be obtained from authors. We excluded studies including patients with bleeding disorders, patients on chronic steroid therapy, or patients in whom steroids were locally injected or sprayed on the tonsillar bed. Eligibility was not restricted by language, type of publication (for example, abstracts or full publications), or patients' age.

The primary outcome was the incidence of postoperative bleeding from the tonsillar fossa (any type of bleeding and of any severity). The secondary outcomes were the incidence of admission for bleeding episodes, operative reinterventions for bleeding episodes, red blood cells transfusion, and mortality. We defined an operative reintervention for a bleeding episode as any surgical procedure performed in the operating room or in the emergency department to stop bleeding from the surgical site. Patients requiring a reintervention in the operating room were considered being admitted to hospital after the procedure, and were included in the meta-analysis of admissions for bleeding episodes.

Data abstraction
----------------

We developed a data abstraction form to standardise the data collection process, which was pilot tested on a landmark publication.[@ref12] For comparison purposes, all steroid doses were converted in dexamethasone equivalents. We converted fixed doses to mg/kg using the mean weight, when the data were provided. If weight was not provided, we used a standard weight of 60 kg for women and 70 kg for men in adults, and weight charts for children to estimate whether the mean dose was lower or greater than 0.5 mg/kg. Bleeding events that occurred on postoperative day zero, or within the first 24 hours, were considered as primary bleeding episodes. Episodes beyond that period of time were defined as secondary bleeding episodes. We contacted the corresponding authors of included studies if data were missing for bleeding episodes, admission, reintervention, red blood cells transfusion, or mortality, or if the methods required clarification. Two reviewers (JP, LV) performed the data collection process independently, and a third reviewer (AFT) resolved any discrepancies. A translator was consulted for studies published in languages other than English or French.

Risk of bias assessment
-----------------------

The risk of bias was assessed independently by two reviewers (JP, LV) using the Cochrane Collaboration's risk of bias tool.[@ref16] Since the objective of the current review was to identify bleeding complications occurring in the acute and subacute perioperative period, studies with considerable numbers of patients lost to follow-up, as well as those with a short follow-up period (\<24 h) were considered to have an increased risk of bias because of their potential for missed bleeding events.[@ref16] For this reason, we assigned an "unclear" overall risk of bias to studies with a proportion of lost to follow-up greater than 10% (incomplete outcome data).

Data synthesis
--------------

Data were analysed using Cochrane Review Manager version 5.0 (Cochrane Collaboration) and summarised using Peto fixed effects models, appropriate for meta-analysis of rare events.[@ref18] We applied a continuity correction of 0.5 to studies reporting no event in both groups. All data were dichotomous, and associations were presented using odds ratio with 95% confidence intervals. An odds ratio greater than 1 implies greater risk in the steroid group, and an odds ratio less than 1 implies greater risk in the control group. We assessed the presence of heterogeneity using the I² statistic, which estimates the percentage of variation between study results that is due to heterogeneity rather than sampling error.[@ref19] We did sensitivity analyses, based on clinical (adults *v* children, cold or combined *v* hot dissection, high \[\>0.5 mg/kg\] *v* low \[≤0.5 mg/kg\] dose steroids, non-steroidal anti-inflammatory drug administration, type of comparator, and timing of bleeding) and methodological (risk of bias, blinding, sample size, and short \[≤24 h\] *v* long \[\>24 h\] follow-up) characteristics, to understand potential sources of heterogeneity and to evaluate the robustness of the results. Potential publication bias was assessed using funnel plot analyses.[@ref20]

Quality of evidence
-------------------

We graded the quality of evidence for the three main outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [@ref21] with GRADEpro software (version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008).

Results
=======

Search results
--------------

We retrieved a total of 1387 citations (fig 1[](#fig1){ref-type="fig"}). Fifty one studies were considered potentially eligible. Of these studies, 16 were excluded because they did not report bleeding episodes nor admission or reintervention, and this information could not be obtained despite attempts to contact the authors. The remaining excluded publications did not meet all inclusion criteria.[@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] We included 29 studies in this systematic review,[@ref12] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] representing 2674 patients (table 1[](#tbl1){ref-type="table"}).

![**Fig 1** Flow diagram of studies](plaj002354.f1_default){#fig1}

###### 

 Characteristics of included studies in meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (reference)                  No of participants   Age inclusion criteria (years)   Procedure             Dissection technique   Drug regimen                                    NSAID use                                                                                                                                                                                           Duration of follow-up                                                                                                                   Bleeding outcome definition                                                                   
  ---------------------------------- -------------------- -------------------------------- --------------------- ---------------------- ----------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ----------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  Catlin et al. (1991)^32^           10                   15                               4 to 12               T, or T and A          Combined                                        Dexamethasone IV, 8 mg/m², before induction                                                                                                                                                         Placebo                                                                                                                                 No                                                        3 weeks                             NR

  Volk et al. (1993)^55^             25                   25                               4 to 12               T, or T and A          Combined                                        Dexamethasone IV, 10 mg, at induction                                                                                                                                                               Placebo                                                                                                                                 No                                                        7 to 10 days                        NR

  Ohlms et al. (1995)^47^            34                   35                               3 to 18               T, or T and A          Cold, combined                                  Dexamethasone IV, 0.5 mg/kg (max 12 mg), immediately before surgery                                                                                                                                 Placebo                                                                                                                                 No                                                        3 to 4 weeks                        NR

  April et al. (1996)^30^            41                   39                               3 to 15               T and A                Hot                                             Dexamethasone IV, 1 mg/kg (max 16 mg), after induction                                                                                                                                              Placebo                                                                                                                                 NR                                                        24 h                                NR

  Tom et al. (1996)^53^              26                   32                               1 to 18               T and A                Hot                                             Dexamethasone IV, 1 mg/kg (max 10 mg), after induction                                                                                                                                              Placebo                                                                                                                                 No                                                        10 days                             NR

  Kim et al. (1998)^39^              40                   20                               3 to 15               T, or T and A          Combined                                        Dexamethasone IV, 1 mg/kg (max 15 mg), after induction or in the postanaesthetic care unit                                                                                                          No treatment or placebo                                                                                                                 Yes                                                       3 days                              NR

  Carr et al. (1999)^31^             15                   14                               Adults                T                      Hot                                             Dexamethasone IV, 20 mg, during surgery                                                                                                                                                             Placebo                                                                                                                                 No                                                        10 days                             NR

  Holt et al. (2000)^36^             68                   60                               2 to 14               T, or T and A          Cold                                            Tropisetron and dexamethasone IV, 0.5 mg/kg (max 8 mg), after induction                                                                                                                             Tropisetron alone,\                                                                                                                     NR                                                        6 days                              NR
                                                                                                                                                                                                                                                                                                                                                                                            0.1 mg/kg (max 2 mg)                                                                                                                                                                                                                  

  Nawasreh et al. (2000)^46^         62                   58                               4 to 14               T, or T and A          Hot                                             Dexamethasone IV, 1 mg/kg (max 16 mg), 1 h before surgery                                                                                                                                           Placebo                                                                                                                                 NR                                                        24 h                                NR

  Palme et al. (2000)^48^            25                   25                               ≥5                    T, or T and A          Hot, combined                                   Prednisolone given orally, 10 mg daily (age 5-11 years) or 0.5 mg/kg daily (age ≥12 years), postoperative day 1 to 7                                                                                Placebo                                                                                                                                 No                                                        2 weeks                             NR

  Giannoni et al. (2002)^33^         25                   25                               3 to 15               T                      Hot                                             Dexamethasone IV, 1 mg/kg (max 16 mg), after induction                                                                                                                                              Placebo                                                                                                                                 Yes                                                       10 days                             NR

  Güne et al. (2002)^34^             15                   45                               3 to 12               T                      NR                                              Dexamethasone IV, 0.15 mg/kg, after induction                                                                                                                                                       3 groups: placebo, ondansetron, 0.15 mg/kg, or droperidol, 0.075 mg/kg                                                                  NR                                                        6 h                                 NR

  Stewart et al. (2002)^52^          132                  68                               ≥16                   T                      Hot                                             Dexamethasone alone or dexamethasone and piroxicam (same dose as controls); dexamethasone IV, 8 mg at induction, 2 mg on the night of surgery, 2 mg twice daily for 4 days, 2 mg daily for 4 days   Piroxicam alone, given orally:\                                                                                                         Yes                                                       2 weeks                             NR
                                                                                                                                                                                                                                                                                                                                                                                            10 mg given 2 h before surgery, 10 mg given on the night of surgery; 10 mg given twice daily for 4 days; 10 mg given daily for 4 days                                                                                                 

  Hanasono et al. (2004)^35^         106                  113                              ≤12                   T, or T and A          Hot, combined                                   Dexamethasone IV, 1 mg/kg (max 50 mg), at the start of surgery                                                                                                                                      Placebo                                                                                                                                 NR                                                        3 days                              NR

  Samarkandi et al. (2004)^51^       29                   31                               2 to 12               T                      Hot                                             Dexamethasone IV, 0.5 mg/kg, after induction                                                                                                                                                        Placebo                                                                                                                                 NR                                                        24 h                                NR

  Malde et al. (2005)^41^            45                   45                               \>3                   T                      Cold                                            Dexamethasone IV, 0.15 mg/kg, after induction                                                                                                                                                       Placebo                                                                                                                                 NR                                                        7 days                              NR

  Trujillo et al. (2005)^54^         35                   34                               3 to 15               T, or T and A          NR                                              Dexamethasone IV; 1 mg/kg (max 8 mg); immediately before surgery, 8 h after operation, 16 h after operation                                                                                         Placebo                                                                                                                                 NR                                                        6 days                              NR

  Kaan et al. (2006)^37^             32                   30                               4 to 12               T, or T and A          Cold                                            Dexamethasone IV, 0.5 mg/kg (max 16 mg), after induction                                                                                                                                            Placebo                                                                                                                                 NR                                                        8 h                                 NR

  Kaufmann et al. (2006)^38^         101                  103                              2 to 16               T and A                NR                                              Dexamethasone IV, 0.5 mg/kg (max 10 mg), during surgery                                                                                                                                             No treatment or placebo                                                                                                                 NR                                                        10 days                             NR

  McKean et al. (2006)^43^           37                   35                               16 to 70              T                      Combined                                        Dexamethasone IV, 10 mg, at induction                                                                                                                                                               Placebo                                                                                                                                 Yes                                                       7 days                              NR

  Mohammad et al. (2006)^45^         25                   25                               3 to 18               T, or T and A          Cold, combined                                  Dexamethasone IV, 1 mg/kg (max 12 mg), during surgery                                                                                                                                               Unclear\                                                                                                                                Yes (steroid group 20%, controls 52%)                     24 h                                NR
                                                                                                                                                                                                                                                                                                                                                                                            (placebo or no drug)                                                                                                                                                                                                                  

  Alajmi et al. (2008)^28^           42                   38                               5 to 18               T, or T and A          Cold, combined                                  Dexamethasone IV, 1 mg/kg (max 16 mg), after induction                                                                                                                                              Placebo                                                                                                                                 Yes (steroid group 14.3%, controls 47.4%)                 16 days                             NR

  Czarnetzki et al. (2008)^12^       161                  54                               2 to 17               T, or T and A          Cold, hot, combined                             3 groups: dexamethasone IV, 0.05 mg/kg, 0.15 mg/kg, 0.5 mg/kg (max 20 mg); after induction                                                                                                          Placebo                                                                                                                                 Yes (steroid subgroups 38%, 43%, and 38%; controls 65%)   10 days                             History of bleeding leading to readmission, with or without evidence of bleeding at examination or need for emergency reoperation

  Lachance et al. (2008)^40^         41                   61                               18 to 45              T                      Combined, 2 cold dissections in control group   Dexamethasone IV (8 mg during surgery), dexamethasone given orally (8 mg at home on day of surgery; 6, 4, and 2 mg twice daily on postoperative days 1, 2, and 3, respectively)                     Placebo                                                                                                                                 No                                                        7 days                              NR

  Rujirojindakul et al. (2008)^50^   25                   25                               15 to 60              T                      Hot                                             Dexamethasone IV, 20 mg, after induction                                                                                                                                                            Placebo                                                                                                                                 No                                                        7 days                              NR

  Ammar et al. (2009)^29^            30                   30                               Adults and children   T, or T and A          Cold                                            Dexamethasone IV, 5 mg to children, 10 mg to adults, for 4 days after surgery                                                                                                                       Placebo                                                                                                                                 Yes                                                       5 days                              NR

  Mohamed et al. (2009)^44^          100                  50                               2 to 12               T, or T and A          Hot                                             2 groups: dexamethasone alone or dexamethasone and glossopharyngeal nerve block (same dose as controls); dexamethasone IV, 0.15mg/kg (max 8 mg), before surgery                                     Bilateral glossopharyngeal nerve block alone with 3 mL of 0.5% bupivacaine                                                              No                                                        Until discharge time (up to 24 h)   NR

  Rabbani et al. (2010)^49^          30                   30                               Adults and children   T, or T and A          NR                                              Dexamethasone IV, 0.1 mg/kg for age \<12 years or 8 mg for \>12 years, at induction                                                                                                                 Ondansetron, 0.1 mg/kg for age \<12 years, 4 mg for age \>12 years                                                                      NR                                                        24 h                                NR

  Mathiesen et al. (2011)^42^        48                   99                               18 to 50              T                      Combined                                        Dexamethasone IV, 8 mg, with paracetamol and pregabalin (same dose as controls) before induction                                                                                                    2 groups: paracetamol alone, 1000 mg, or paracetamol and pregabalin, 300 mg                                                             No                                                        2 weeks                             Bleeding episodes requiring reoperation
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A=adenoidectomy; cold=dissection with cold steel instruments, haemostasis with gauze compression, or ligatures; combined=cold dissection with use of electrocautery for haemostasis; hot=dissection and haemostasis with electric device; IV=intravenous; max=maximum; NR=not reported; NSAID=non-steroidal anti-inflammatory drug; T=tonsillectomy.

Study characteristics
---------------------

Of the included studies, 24 were published in English, and one each in Turkish,[@ref34] Korean,[@ref39] Spanish,[@ref54] Chinese,[@ref29] and Hebrew.[@ref38] Ten studies were conducted in North America,[@ref30] [@ref31] [@ref32] [@ref33] [@ref35] [@ref40] [@ref47] [@ref53] [@ref54] [@ref55] 12 in Asia,[@ref28] [@ref29] [@ref34] [@ref37] [@ref38] [@ref39] [@ref41] [@ref45] [@ref46] [@ref49] [@ref50] [@ref51] four in Europe,[@ref12] [@ref42] [@ref43] [@ref52] two in Australia,[@ref36] [@ref48] and one in Africa.[@ref44] All studies were presented as full publications. In two studies, dexamethasone was provided by pharmaceutical companies,[@ref12] [@ref32] and one of these studies specified that the funding organisation had no role in the design or conduct of the study.[@ref12]

Nineteen studies were performed in children, six in adults only, and four included both children and adults. Twenty four studies compared the effects of systemic steroids with placebo[@ref12] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref37] [@ref40] [@ref41] [@ref43] [@ref46] [@ref47] [@ref48] [@ref50] [@ref51] [@ref53] [@ref54] [@ref55] or no intervention (neither a placebo nor any intervention in the control group).[@ref38] [@ref39] [@ref45] Six studies compared systemic steroids with other treatments (tropisetron, ondansetron, droperidol, piroxicam, bilateral glossopharyngeal nerve block with bupivacaine, or paracetamol).

Dexamethasone was used in 28 studies, while prednisolone was administered in the remaining study.[@ref48] In 18 studies, the dexamethasone dose was calculated according to the patient's weight (mg/kg) and varied from 0.05 mg/kg [@ref12] to 1.0 mg/kg. In the remaining studies, the steroid dose was fixed[@ref29] [@ref31] [@ref40] [@ref42] [@ref43] [@ref50] [@ref52] [@ref55]; based on the patient's body surface (mg/m²)[@ref32]; or either fixed or based on weight (mg/kg), according to patient's age.[@ref48] [@ref49] Systemic steroids were administrated as a single dose, or repeated doses over a specific period of time: 16 h,[@ref54] three days,[@ref40] four days,[@ref29] seven days,[@ref48] or eight days.[@ref52] In these studies, the total dose was taken into account.

In most studies, the main outcomes were the effect of steroids on pain,[@ref12] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref35] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref47] [@ref48] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] nausea and vomiting,[@ref12] [@ref28] [@ref30] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref41] [@ref43] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] and oral intake [@ref12] [@ref28] [@ref30] [@ref32] [@ref35] [@ref37] [@ref38] [@ref39] [@ref41] [@ref43] [@ref45] [@ref46] [@ref47] [@ref48] [@ref50] [@ref51] [@ref53] [@ref55] after tonsillectomy. Other main outcome measures of included studies were the effect of steroids on oedema, fever, trismus, halitosis, and level of activity.

Twenty six studies reported data for post-tonsillectomy bleeding. Through private communications with authors, we obtained details pertaining to the severity of and to interventions related to the bleeding episodes for three of these studies,[@ref40] [@ref42] [@ref53] and obtained unpublished data on bleeding episodes for three additional studies.[@ref43] [@ref44] [@ref49] Eight studies reported no postoperative bleeding episodes or mentioned uneventful surgeries.[@ref29] [@ref37] [@ref43] [@ref44] [@ref48] [@ref49] [@ref51] [@ref54] Among studies reporting bleeding episodes, 18 specified the timing of occurrence,[@ref12] [@ref28] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref39] [@ref41] [@ref42] [@ref45] [@ref46] [@ref47] [@ref50] [@ref52] [@ref53] nine reported the need for admission due to bleeding,[@ref12] [@ref28] [@ref30] [@ref31] [@ref35] [@ref46] [@ref47] [@ref50] [@ref53] and 12 reported data for reintervention.[@ref12] [@ref30] [@ref32] [@ref34] [@ref39] [@ref40] [@ref42] [@ref46] [@ref47] [@ref50] [@ref52] [@ref55] No study reported transfusion of red blood cells or mortality.

A clear definition of post-tonsillectomy bleeding was presented in two of 29 studies.[@ref12] [@ref42] Eight studies stated that bleeding episodes were going to be reported,[@ref12] [@ref28] [@ref31] [@ref32] [@ref33] [@ref35] [@ref37] [@ref41] while six clearly questioned their patients about postoperative bleeding or provided instructions in the event of unexpected bleeding.[@ref12] [@ref28] [@ref35] [@ref37] [@ref41] [@ref42] No study described a systematic method to evaluate postoperative bleeding.

Validity assessment
-------------------

A low risk of bias was attributed to seven studies [@ref33] [@ref35] [@ref36] [@ref40] [@ref41] [@ref42] [@ref50] (table 2[](#tbl2){ref-type="table"}). Fifteen studies had an adequate sequence generation,[@ref12] [@ref30] [@ref31] [@ref33] [@ref35] [@ref36] [@ref37] [@ref40] [@ref41] [@ref42] [@ref43] [@ref50] [@ref51] [@ref52] [@ref54] and 15 had an appropriate method of allocation concealment.[@ref12] [@ref30] [@ref33] [@ref35] [@ref36] [@ref40] [@ref41] [@ref42] [@ref43] [@ref47] [@ref48] [@ref50] [@ref52] [@ref53] [@ref55] Six studies were not blinded,[@ref28] [@ref38] [@ref39] [@ref45] [@ref46] [@ref49] and blinding was unclear in another study.[@ref34] One study was terminated early because of an increased incidence of post-tonsillectomy bleeding in the intervention group.[@ref12] Fourteen studies [@ref12] [@ref31] [@ref32] [@ref33] [@ref36] [@ref38] [@ref40] [@ref41] [@ref42] [@ref43] [@ref47] [@ref52] [@ref53] [@ref55] reported losses to follow-up that varied from 2.7%[@ref12] to 36.1%,[@ref43] and losses to follow-up were unclear in four studies.[@ref29] [@ref39] [@ref45] [@ref48] Eight studies had a follow-up period of 24 h or less.[@ref30] [@ref34] [@ref37] [@ref44] [@ref45] [@ref46] [@ref49] [@ref51] Two studies reported performing an intention to treat analysis.[@ref12] [@ref40] Five studies did not report all outcomes stated in their methods.[@ref32] [@ref45] [@ref46] [@ref51] [@ref54]

###### 

 Risk of bias and methodological quality assessment of included studies

  Study (reference)                  Sequence generation   Allocation concealment   Blinding   Incomplete outcome data   Selective reporting   Other bias   Follow-up period (\>24 h)   Summary
  ---------------------------------- --------------------- ------------------------ ---------- ------------------------- --------------------- ------------ --------------------------- ---------
  Catlin et al. (1991)^32^           Unclear               Unclear                  Low        High                      Unclear               Unclear      Low                         Unclear
  Volk et al. (1993)^55^             Unclear               Low                      Low        High                      Low                   High         Low                         Unclear
  Ohlms et al. (1995)^47^            Unclear               Low                      Low        High                      Low                   Low          Low                         Unclear
  April et al. (1996)^30^            Low                   Low                      Low        Low                       Low                   Low          High                        High
  Tom et al. (1996)^53^              Unclear               Low                      Low        High                      Low                   Unclear      Low                         Unclear
  Kim et al. (1998)^39^              Unclear               High                     High       Unclear                   Low                   High         Low                         High
  Carr et al. (1999)^31^             Low                   Unclear                  Low        High                      Low                   Low          Low                         Unclear
  Holt et al. (2000)^36^             Low                   Low                      Low        Low                       Low                   Low          Low                         Low
  Nawasreh et al. (2000)^46^         Unclear               High                     High       Low                       High                  Unclear      High                        High
  Palme et al. (2000)^48^            Unclear               Low                      Low        Unclear                   Low                   Unclear      Low                         Unclear
  Giannoni et al. (2002)^33^         Low                   Low                      Low        Low                       Low                   Low          Low                         Low
  Güne et al. (2002)^34^             Unclear               High                     Unclear    Low                       Low                   Unclear      High                        High
  Stewart et al. (2002)^52^          Low                   Low                      Low        High                      Low                   Low          Low                         Unclear
  Hanasono et al. (2004)^35^         Low                   Low                      Low        Low                       Low                   Low          Low                         Low
  Samarkandi et al. (2004)^51^       Low                   Unclear                  Low        Low                       Unclear               Low          High                        High
  Malde et al. (2005)^41^            Low                   Low                      Low        Low                       Low                   Low          Low                         Low
  Trujillo et al. (2005)^54^         Low                   Unclear                  Low        Low                       Unclear               Low          Low                         Unclear
  Kaan et al. (2006)^37^             Low                   Unclear                  Low        Low                       Low                   Low          High                        High
  Kaufmann et al. (2006)^38^         Unclear               High                     High       High                      Low                   High         Low                         High
  McKean et al. (2006)^43^           Low                   Low                      Low        High                      Low                   Low          Low                         Unclear
  Mohammad et al. (2006)^45^         Unclear               Unclear                  High       Unclear                   Unclear               High         Unclear                     High
  Alajmi et al. (2008)^28^           High                  High                     High       Low                       Low                   High         Low                         High
  Czarnetzki et al. (2008)^12^       Low                   Low                      Low        Low                       Low                   High         Low                         Unclear
  Lachance et al. (2008)^40^         Low                   Low                      Low        Low                       Low                   Low          Low                         Low
  Rujirojindakul et al. (2008)^50^   Low                   Low                      Low        Low                       Low                   Low          Low                         Low
  Ammar et al. (2009)^29^            Unclear               Unclear                  Low        Unclear                   Low                   Low          Low                         Unclear
  Mohamed et al. (2009)^44^          Unclear               High                     Low        Low                       Low                   Low          High                        High
  Rabbani et al. (2010)^49^          High                  High                     High       Low                       Unclear               High         High                        High
  Mathiesen et al. (2011)^42^        Low                   Low                      Low        Low                       Low                   Low          Low                         Low

Post-tonsillectomy bleeding episodes
------------------------------------

The administration of steroids did not increase the incidence of bleeding events after tonsillectomy, based on pooled data from the 29 studies (n=2674, odds ratio 0.96, 95% confidence intervals 0.66 to 1.40, I²=0%), of which eight did not observe any bleeding episodes[@ref29] [@ref37] [@ref43] [@ref44] [@ref48] [@ref49] [@ref51] [@ref54] (fig 2[](#fig2){ref-type="fig"}). Sensitivity analyses including trials with low risk of bias, observers blinded to the intervention, larger population, or longer follow-up periods yielded similar results (table 3[](#tbl3){ref-type="table"}). Results were also comparable regardless of the population age, surgical technique, steroid dose, or concomitant administration of non-steroidal anti-inflammatory drugs. When we analysed primary and secondary bleeding events separately, we observed no increase in bleeding incident with the administration of steroids.

![**Fig 2** Post-tonsillectomy bleeding. For Peto odds ratio, continuity correction k=0.5 was used when there was no event in both groups](plaj002354.f2_default){#fig2}

###### 

 Sensitivity analysis of post-tonsillectomy bleeding outcome

  Subgroups                     No of studies   No of participants   Odds ratio (95% CI)    I^2^ (%)
  ----------------------------- --------------- -------------------- ---------------------- ----------
  Methodological quality                                                                    
   Low risk of bias             7               786                  0.82 (0.38 to 1.74)    0
   High risk of bias            11              986                  0.71 (0.31 to 1.61)    0
  Blinding                                                                                  
   Double blinded               22              2040                 1.04 (0.68 to 1. 56)   0
   No blinding or unclear       7               634                  0.67 (0.27 to 1.70)    0
  Sample size                                                                               
    \<100 patients              20              1189                 1.15 (0.60 to 2.42)    0
    ≥100 patients               9               1485                 0.88 (0.55 to 1.40)    0
  Duration of follow-up                                                                     
   ≤24 h                        8               642                  0.92 (0.30 to 2.82)    0
   \>24 h                       21              2032                 0.96 (0.64 to 1.44)    0
  Age group                                                                                 
   Children only                19              1809                 1.24 (0.74 to 2.08)    0
   Adults only                  6               605                  0.73 (0.41 to 1.30)    0
  Surgical technique                                                                        
   Cold or combine dissection   13              861                  0.82 (0.43 to 1.56)    0
   Hot dissection               9               592                  0.76 (0.42 to 1.40)    0
  Dose regimen of steroid                                                                   
   ≤0.5 mg/kg                   19              1784                 1.05 (0.68 to 1.61)    0
   \>0.5 mg/kg                  9               840                  0.77 (0.34 to 1.74)    0
  Coadministration of NSAID                                                                 
   NSAID                        8               787                  0.92 (0.52 to 1.62)    26
   No NSAID                     20              1683                 1.00 (0.60 to 1.65)    0
  Type of comparator                                                                        
   Placebo                      20              1615                 1.32 (0.80 to 2.20)    0
   Other drugs                  6               745                  0.62 (0.33 to 1.16)    0
  Moment of bleeding episode                                                                
   Primary bleedings            9               952                  0.93 (0.33 to 2.59)    0
   Secondary bleedings          14              1437                 0.97 (0.61 to 1.56)    18

Cold=dissection with cold steel instruments, haemostasis with gauze compression, or ligatures; combined=cold dissection with use of electrocautery for haemostasis; hot=dissection and haemostasis with electric device; NSAID=non-steroidal anti-inflammatory drug.

Hospital admission
------------------

Seventeen studies reported data for admission[@ref12] [@ref28] [@ref30] [@ref31] [@ref35] [@ref46] [@ref47] [@ref50] [@ref53] or reinterventions[@ref34] [@ref36] [@ref39] [@ref40] [@ref42] [@ref45] [@ref52] [@ref55] that required admission (fig 3[](#fig3){ref-type="fig"}). The incidence of admission due to a bleeding episode did not increase in the steroid group (17 studies, n=1722 patients, odds ratio 1.16, 95% confidence interval 0.68 to 2.00, I²=19%). All sensitivity analyses accorded with this finding (data not shown).

![**Fig 3** Admission for post-tonsillectomy bleeding](plaj002354.f3_default){#fig3}

Reintervention for a bleeding episode
-------------------------------------

The incidence of operative reintervention for bleeding episodes was significantly increased in the steroid group (12 studies, n=1178; odds ratio 2.27, 95% confidence interval 1.03 to 4.99, I^2^=0%; fig 4[](#fig4){ref-type="fig"}). The average incidence of reintervention due to bleeding in patients receiving steroids was 3.0% versus 1.5% in controls. Sensitivity analyses were performed to evaluate the incidence of reintervention for bleeding episodes among different subgroups (table 4[](#tbl4){ref-type="table"}). We observed a significant increase of reinterventions in children (eight studies[@ref12] [@ref30] [@ref32] [@ref34] [@ref39] [@ref46] [@ref47] [@ref55]; 3.43, 1.29 to 9.13, I²=0%) but not in adults (four[@ref40] [@ref42] [@ref50] [@ref52]; 1.07, 0.29 to 4.03, I²=0%). A dose effect was not observed. We found an increased incidence of reinterventions among patients receiving non-steroidal anti-inflammatory drugs (three[@ref12] [@ref39] [@ref52]; 4.10, 0.99 to 16.97, I²=0%). No significant association was seen among double blinded studies (nine[@ref12] [@ref30] [@ref32] [@ref40] [@ref42] [@ref47] [@ref50] [@ref52] [@ref55]; 2.22, 0.95 to 5.18, I^2^=0%) and those with longer follow-up periods (nine[@ref12] [@ref32] [@ref39] [@ref40] [@ref42] [@ref47] [@ref50] [@ref52] [@ref55]; 2.16, 0.92 to 5.06, I^2^=0%). In each case, the incidence of reinterventions for bleeding episodes was increased in the steroid group compared with the control group without reaching significance (P=0.07 for double blinding, P=0.08 for longer follow-up periods), although the results suggested a strong trend. Studies with low risk of bias showed no clear association between steroids use and the incidence of operative reintervention (three studies[@ref40] [@ref42] [@ref50]; 0.91, 0.22 to 3.68, I²=0%).

![**Fig 4** Reintervention for post-tonsillectomy bleeding. For Peto odds ratio, continuity correction k=0.5 was used when there was no event in both groups](plaj002354.f4_default){#fig4}

###### 

 Sensitivity analysis of operative reintervention to treat post-tonsillectomy bleeding

  Subgroups                      No of studies   No of participants   Odds ratio (95% CI)    I^2^ (%)
  ------------------------------ --------------- -------------------- ---------------------- ----------
  Methodological quality                                                                     
   Low risk of bias              3               299                  0.91 (0.22 to 3.68)    0
   High risk of bias             4               320                  3.31 (0.51 to 21.61)   0
  Blinding                                                                                   
   Double blinded                9               938                  2.22 (0.95 to 5.18)    0
   No blinding or unclear        3               240                  2.64 (0.31 to 22.41)   0
  Sample size                                                                                
   \<100 patients                7               394                  3.85 (1.13 to 13.17)   0
   ≥100 patients                 5               784                  1.57 (0.56 to 4.38)    0
  Follow-up                                                                                  
   ≤24 h                         3               260                  3.06 (0.37 to 25.07)   0
   \>24 h                        9               918                  2.16 (0.92 to 5.06)    0
  Age group                                                                                  
   Children only                 8               679                  3.43 (1.29 to 9.13)    0
   Adults only                   4               499                  1.07 (0.29 to 4.03)    0
  Surgical technique                                                                         
   Cold or combined dissection   6               453                  1.45 (0.50 to 4.20)    0
   Hot dissection                4               450                  3.84 (0.53 to 28.00)   0
  Dosage regimen of steroid                                                                  
   ≤0.5 mg/kg                    8               816                  2.45 (1.04 to 5.76)    0
   \>0.5 mg/kg                   4               362                  1.52 (0.21 to 11.20)   0
  Coadministration of NSAID                                                                  
   NSAID                         3               475                  4.10 (0.99 to 16.97)   0
   No NSAID                      9               703                  1.75 (0.68 to 4.50)    0

Cold=dissection with cold steel instruments, haemostasis with gauze compression, or ligatures; combined=cold dissection with use of electrocautery for haemostasis; hot=dissection and haemostasis with electric device; NSAID=non-steroidal anti-inflammatory drug.

Allogenic transfusion and mortality
-----------------------------------

None of the included studies reported transfusion of red blood cells or mortality.

Publication bias and quality of evidence
----------------------------------------

We evaluated the presence of potential publication bias using a funnel plot of intervention effect estimates versus the standard error for studies presenting data for bleeding episodes. Visual inspection of the funnel plot did not reveal evidence of publication bias (web figure). According to the GRADE methodology, the quality of the evidence for bleeding and admission outcomes after tonsillectomy was low; however, the association between post-tonsillectomy reintervention and systemic steroids was considered to be of high quality (table 5[](#tbl5){ref-type="table"}).

###### 

 Summary of evidence for key outcomes

  Outcome                                No of participants/studies   Quality of evidence (GRADE)   Summary               
  -------------------------------------- ---------------------------- ----------------------------- --------------------- ---------
  Post-tonsillectomy bleeding episodes   2674/29                      Very low                      0.96 (0.66 to 1.40)   4.6/4.2
  Admission                              1722/17                      Very low                      1.16 (0.68 to 2.00)   4.1/3.1
  Reintervention                         1178/12                      High                          2.27 (1.03 to 4.99)   3.0/1.5

Discussion
==========

In this systematic review, we did not observe an increased incidence of postoperative bleeding events after perioperative administration of systemic steroids in patients undergoing tonsillectomy. However, we did observe a significant increase in the incidence of operative reinterventions needed to manage clinically significant bleeding episodes in patients who received systemic steroids. The quality of the evidence according to the GRADE approach was high for this specific outcome. This raised incidence of reinterventions was significantly increased in children.

Strengths and limitations if the study
--------------------------------------

An important limitation of our study concerned the data available within included publications. None of the included studies was designed to evaluate adverse complications of steroids use after tonsillectomy, and no study systematically screened for bleeding events after tonsillectomy. Therefore, the incidence of this complication could have been systematically underestimated. Moreover, only two studies presented a clear definition of post-tonsillectomy bleeding. Bleeding episodes of varying severity may not have received equal consideration across all studies, which could lead to an underestimation of overall bleeding episodes. This could explain why we did not observe a significant association between steroids use and bleeding events, while we did observe an association with reintervention for bleeding events.

On the other hand, the inclusion in meta-analyses of studies reporting no bleeding event in either group using a continuity correction could have underestimated the association. The majority of included studies were of limited methodological quality, and many studies had substantial numbers of patients who were lost to follow-up. These factors provide further concern that bleeding episodes may have been missed. A significant proportion of studies had a very limited follow-up period precluding the evaluation of the incidence of secondary bleeding episodes. Since bleeding episodes are relatively rare events, unreported episodes could greatly affect the study results.

Despite of known limitations, our systematic review had important strengths. Firstly, the extensive search strategy using different databases, including the grey literature and conference proceedings, allowed us to retrieve a comprehensive list of the studies performed on the topic. Importantly, the decision to evaluate the incidence of reinterventions for bleeding episodes, as opposed to only bleeding episodes, allowed us to summarise the effect of clinically significant bleeding events with greater fidelity. We believe that operative reintervention for bleeding episodes represents a more reliable and clinically meaningful endpoint than bleeding episodes. Severe enough bleeding events to require operative reintervention are less likely to have been overlooked and may therefore represent the optimal clinical outcome to understand the impact of systemic steroids in tonsillectomy.

Comparison with other studies
-----------------------------

Overall, the mean incidence of post-tonsillectomy bleeding events observed in our systematic review was 4.4%, which is consistent with the current literature.[@ref56] [@ref57] [@ref58] [@ref59] [@ref60] Our results on postoperative bleeding are in accordance with a recent systematic review.[@ref15] However, this previous meta-analysis identified half the number of studies as compared with our study, and did not evaluate other clinically significant outcomes such as operative reinterventions for bleeding and hospital admission. The increased incidence of reintervention observed in a recent landmark study by Czarnetzki and colleagues[@ref12] was also seen in our pooled analysis. But our systematic review did not confirm the higher incidence of bleeding episodes associated with perioperative steroids use in tonsillectomy procedures, as observed in this trial.

The increased incidence of reinterventions associated with steroids occurred in the absence of increased bleeding events, and thus probably represents an increased severity of bleeding when steroids are administered. Although no study specified indications to undergo a reintervention in the event of bleeding, this procedure usually suggests that the bleeding was significant enough to require an emergency procedure. Bleeding events requiring reintervention are more likely to be noticed and reported in a publication as opposed to minor events. Therefore, reinterventions to manage bleeding events may be a more objective and reliable outcome to assess clinically significant bleeding events after tonsillectomy.

Conclusions and policy implications
-----------------------------------

We did not observe an increased incidence of postoperative bleeding events following administration of systemic steroids during tonsillectomy. We did, however, observe a significant increase in the incidence of operative reintervention associated with the use of steroids, which may be related to an increased severity of a given bleeding episode. Considering the potential for harm and the availability of other drugs to prevent postoperative nausea and vomiting, we recommend that steroids should be used with caution; risks and benefits must be weighted; and steroids should not be used routinely for such purposes, especially in children. Further studies should be designed to answer concerns about the safety of the perioperative use of steroids in tonsillectomy procedures.

### What is already known on this topic

1.  Tonsillectomy is one of the most commonly performed ear, nose, and throat surgeries worldwide, but has a high underlying risk of postoperative nausea and vomiting

2.  Systemic use of steroids to reduce postoperative nausea and vomiting is increasing, and recommended in addition to the use of 5-HT~3~ antagonists in recent guidelines

3.  A recent study has linked such use of steroids with an increased incidence of postoperative bleeding after tonsillectomy

### What this study adds

1.  Overall, the risk of postoperative bleeding did not increase after perioperative administration of systemic steroids in patients undergoing tonsillectomy

2.  However, the incidence of reinterventions for bleeding episodes did increase overall with steroids, and especially among children, which could represent a greater severity of bleeding associated with use of steroids

3.  Systemic steroids should be used with caution; risks and benefits must be weighted, and steroids should not be used routinely to prevent postoperative nausea and vomiting after tonsillectomy, especially in children
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